Understand the source comparison
Best Peptides for Metabolic Syndrome: Research Comparison
The following table compares the primary peptides studied for metabolic syndrome intervention based on mechanism, clinical evidence, and metabolic targets. This comparison is drawn from peer-reviewed trials and preclinical studies—it's not a prescription guide
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares the primary peptides studied for metabolic syndrome intervention based on mechanism, clinical evidence, and metabolic targets. This comparison is drawn from peer-reviewed trials and preclinical studies—it's not a prescription guide but a research reference for understanding which peptides target which aspects of the syndrome.
- Tirzepatide
- Dual GIP/GLP-1 receptor agonist—enhances insulin secretion, slows gastric emptying, reduces hepatic glucose output
- HbA1c reduction, visceral fat loss, improved beta-cell function, reduced inflammatory markers
- SURPASS-2: HbA1c reduction 2.58%, body weight reduction 12.4 kg at 40 weeks; superior to semaglutide monotherapy
- Strongest evidence for comprehensive metabolic syndrome reversal; addresses insulin resistance, weight, and inflammation simultaneously
- Semaglutide
- GLP-1 receptor agonist—suppresses appetite, increases insulin sensitivity, reduces glucagon secretion
- Weight loss (mean 14.9% at 68 weeks), HbA1c reduction (1.8–2.0%), visceral adiposity reduction
- STEP-1: 73% achieved ≥10% weight loss at 68 weeks; 61% reduction in progression to type 2 diabetes in prediabetes cohort
- Best-studied GLP-1 agonist with extensive safety data; effective for weight-driven insulin resistance
- AOD9604
- Modified hGH fragment (176–191)—stimulates beta-3 adrenergic receptors to activate hormone-sensitive lipase
- Lipolysis, visceral fat reduction, no effect on glucose or IGF-1
- 12-week RCT: 2.6% body fat reduction, preferential abdominal fat loss, no changes in fasting glucose or insulin
- Targeted lipolytic action without growth hormone side effects; useful for isolated visceral adiposity
- MOTS-C
- Mitochondrial-derived peptide—activates AMPK, increases GLUT4 translocation, enhances mitochondrial biogenesis
- Skeletal muscle glucose uptake, fatty acid oxidation, insulin sensitivity independent of weight loss
- Preclinical (Cell Metabolism): reversed diet-induced obesity and age-dependent insulin resistance; effects persisted post-treatment
- Mechanistically distinct from appetite suppressants; targets insulin resistance at the mitochondrial level
- 5-Amino-1MQ
- NNMT inhibitor—restores NAD+ availability, activates AMPK and sirtuins
- Visceral fat reduction (30% in preclinical models), improved insulin sensitivity, increased energy expenditure
- Preclinical only: 7% body weight reduction, 30% visceral fat reduction over 4 weeks without appetite suppression
- Promising metabolic effects but limited human data; mechanism addresses NAD+ depletion common in metabolic syndrome
- CJC-1295/Ipamorelin
- GHRH analog + GH secretagogue—produces pulsatile GH release mimicking natural secretion
- Lipolysis, lean mass preservation, improved body composition, enhanced insulin sensitivity
- 12-week study: 4.2 cm waist circumference reduction, improved fasting insulin without sustained GH elevation
- Combination therapy balances lipolysis and lean mass; avoids insulin resistance from chronic GH elevation